Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.

Share this video  

ASCO 2016 | CASTOR and POLLUX trial results for multiple myeloma reported at ASCO and EHA

Keith Stewart • 3 Jun 2016
ASCO 2016
Multiple Myeloma Antibodies Bortezomib Daratumumab Lenalidomide
CASTOR POLLUX

Keith Stewart, MB, ChB from the Mayo Clinic, Scottsdale, AZ summarizes the results of two Phase III trials of daratumumab in multiple myeloma (MM) reported at ASCO and EHA. The CASTOR study (NCT02136134) reported at ASCO 2016 looks at the combination of daratumumab with bortezomib and dexamethasone vs bortezomib and dexamethasone. The results show that the addition of daratumumab to bortezomib in relapsed patients, improves response rate and progression-free survival (PFS). The POLLUX trial (NCT02076009) looking at daratumumab with lenalidomide and dexamethasone vs lenalidomide and dexamethasone reported at EHA 2016, also show improved response and PFS.
Recorded at the American Society of Oncology (ASCO) 2016 Annual Meeting held in Chicago, IL.

More from Keith Stewart

The future of myeloma therapy
Brian Walker et al. • 15 Apr 2023
Day 2 wrap-up: pushing myeloma boundaries 10:38
Day 2 wrap-up: pushing myeloma boundaries
Gareth Morgan et al. • 27 Mar 2022
Day 1 highlights: peripheral blood MRD, AB amyloid treatment, single-cell & metabolomics 11:10
Day 1 highlights: peripheral blood MRD, AB amyloid treatment, single-cell & metabolomics
Faith Davies et al. • 26 Mar 2022
Immunotherapy in myeloma – where are we? 3:09
Immunotherapy in myeloma – where are we?
Keith Stewart • 30 Apr 2020

Related Videos

The FDA approval of daratumumab for high-risk smoldering myeloma based on the AQUILA trial 10:22
The FDA approval of daratumumab for high-risk smoldering myeloma based on the AQUILA trial
Peter Voorhees • 19 Nov 2025
Promising approaches being explored in high-risk myeloma & trials to look out for 2:11
Promising approaches being explored in high-risk myeloma & trials to look out for
Sham Mailankody • 24 Oct 2025
The value of extensive profiling in single-arm trials for high-risk myeloma 2:39
The value of extensive profiling in single-arm trials for high-risk myeloma
Martin Kaiser • 24 Oct 2025
How is the definition of high-risk myeloma evolving in the era of CAR T-cell therapy? 2:35
How is the definition of high-risk myeloma evolving in the era of CAR T-cell therapy?
Sham Mailankody • 24 Oct 2025
The content of VJHemOnc is intended for healthcare professionals